Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares traded down 2.4% during trading on Wednesday . The stock traded as low as $1.22 and last traded at $1.24. 528 shares were traded during trading, a decline of 100% from the average session volume of 314,712 shares. The stock had previously closed at $1.27.
Several research analysts have recently commented on the stock. ValuEngine lowered shares of Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 4th. Ascendiant Capital Markets assumed coverage on shares of Outlook Therapeutics in a research note on Monday, April 22nd. They set a “buy” rating and a $4.00 price target on the stock.
Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings results on Thursday, February 14th. The company reported ($0.80) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.48) by $1.68. The business had revenue of $1.07 million for the quarter.
TRADEMARK VIOLATION NOTICE: “Outlook Therapeutics (OTLK) Trading Down 2.4%” was first posted by Mayfield Recorder and is owned by of Mayfield Recorder. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://mayfieldrecorder.com/2019/05/10/outlook-therapeutics-otlk-trading-down-2-4.html.
About Outlook Therapeutics (NASDAQ:OTLK)
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Further Reading: Trading signals using Bollinger bands
Receive News & Ratings for Outlook Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outlook Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.